Cabot  Brown net worth and biography

Cabot Brown Biography and Net Worth

Director of GW Pharmaceuticals

Cabot Brown has served as a Non-Executive Director since February 2013. Mr. Brown has over 25 years of experience in the financial industry.

Mr. Brown is the Founder and Chief Executive Officer of Carabiner LLC, an advisory and private equity firm based in San Francisco and London that specializes in health care and education. Previously, Mr. Brown served as a Managing Director at GCA Savvian Group Corp., an international financial advisory firm, from 2011 to 2012 where he directed the firm's efforts in the health care industry. Before joining GCA Savvian, Mr. Brown worked for ten years at Seven Hills Group, an investment banking group he co-founded where he also directed the firm's health care activities. He also was Managing Director of Brown, McMillan & Co., an investment firm he co-founded that sponsored buy-outs and venture capital investments. From 1987 until 1995, Mr. Brown worked at Volpe, Welty & Company, a boutique investment bank where he co-founded and ran the health care practice and served as a member of its Executive Committee.

Mr. Brown started his finance career in New York, working in the investment banking departments of The First Boston Corporation and Lehman Brothers.

Mr. Brown holds an M.B.A. from Harvard Business School with high distinction as a George F. Baker Scholar and an A.B. cum laude in Government from Harvard College. Our board of directors believes Mr. Brown's qualifications to serve as a member of our board include his financial expertise, his extensive experience in the health care industry and his years of experience in his leadership roles as a director and executive officer.

What is Cabot Brown's net worth?

The estimated net worth of Cabot Brown is at least $1.58 million as of March 18th, 2021. Mr. Brown owns 7,200 shares of GW Pharmaceuticals stock worth more than $1,576,512 as of November 16th. This net worth estimate does not reflect any other assets that Mr. Brown may own. Learn More about Cabot Brown's net worth.

How do I contact Cabot Brown?

The corporate mailing address for Mr. Brown and other GW Pharmaceuticals executives is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. GW Pharmaceuticals can also be reached via phone at 44-12-2326-6800 and via email at [email protected]. Learn More on Cabot Brown's contact information.

Has Cabot Brown been buying or selling shares of GW Pharmaceuticals?

Cabot Brown has not been actively trading shares of GW Pharmaceuticals during the past quarter. Most recently, Cabot Brown sold 4,020 shares of the business's stock in a transaction on Thursday, March 18th. The shares were sold at an average price of $17.95, for a transaction totalling $72,159.00. Following the completion of the sale, the director now directly owns 7,200 shares of the company's stock, valued at $129,240. Learn More on Cabot Brown's trading history.

Who are GW Pharmaceuticals' active insiders?

GW Pharmaceuticals' insider roster includes Cabot Brown (Director), Adam George (Insider), Justin Gover (CEO), Geoffrey Guy (Chairman), Volker Knappertz (Director), Douglas Snyder (Insider), and Christopher Tovey (COO). Learn More on GW Pharmaceuticals' active insiders.

Cabot Brown Insider Trading History at GW Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/18/2021Sell4,020$17.95$72,159.007,200View SEC Filing Icon  
1/3/2020Sell3,576$8.58$30,682.0820,232View SEC Filing Icon  
3/1/2019Sell52,104$14.38$749,255.5221,679View SEC Filing Icon  
See Full Table

Cabot Brown Buying and Selling Activity at GW Pharmaceuticals

This chart shows Cabot Brown's buying and selling at GW Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

GW Pharmaceuticals Company Overview

GW Pharmaceuticals logo
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $218.96
Low: $218.96
High: $218.96

50 Day Range

MA: $218.59
Low: $216.90
High: $219.28

2 Week Range

Now: $218.96
Low: $87.07
High: $219.57

Volume

N/A

Average Volume

899,771 shs

Market Capitalization

$6.86 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15